Multiple sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system. It is triggered by certain T cells, which infiltrate the brain and spinal cord and attack the insulating myelin sheath around axons. […]
Brigham researchers are working on a new approach to target autoimmunity in the brain leverages designer bacteria to make treatment safer and more effective Researchers from Brigham and Women’s Hospital, a founding member of the Mass General […]
Bactolife A/S (“Bactolife”), a bioindustrial company developing proprietary Binding ProteinsTM, which strengthen the gut microbiome of humans and animals with the aim of reducing the burden of gastrointestinal infections and anti-microbial resistance, today announced that […]
About one in two women are affected by cystitis during her lifetime, and many suffer from recurrent urinary tract infections. Bladder infections are not only painful and potentially dangerous, but they also pose a significant […]
The Dutch government has reserved €200 million from its National Growth Fund for the establishment of the Holomicrobiome Institute and its activities during the first ten years. The reservation was announced by Minister Adriaansens of […]
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks of growth retardation, sepsis and NEC which leads to increased mortality. Hospital stays for these […]
Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, […]
Exeliom Biosciences (formerly Nextbiotix), a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies, announced the completion of its €24 million ($26 million) Series A with a last extension […]
Pendulum Therapeutics, the biotech company pioneering the next frontier of metabolic health through its microbiome-targeted products, announced a strategic partnership with New Zealand dairy nutrition company Fonterra. Fonterra will invest $10 million into the growth-stage […]
Concerto Biosciences announced the launch of a discovery endeavor to develop a new microbial product for the treatment of vulvovaginal candidiasis (VVC), a vaginal yeast infection that adversely affects 75% of women at some point […]
Freya Biosciences, a trans-Atlantic biotech company specializing in women’s health, announces positive topline results from its first Phase 1 clinical study of its lead asset FB101, an investigational vaginal microbial immunotherapeutic. These data allow the […]